Clinicians Treating Refractory Relapse ALL Should Consider Using Inotuzumab

Clinicians Treating Refractory Relapse ALL Should Consider Using Inotuzumab

Cancer-News

2 years
338 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.
Up Next Autoplay